Open AccessClinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
Author(s) -
Bourlon Maria T.,
Gao Dexiang,
Trigero Sara,
Clemons Julia E.,
Breaker Kathryn,
Lam Elaine T.,
Flaig Thomas W.
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.919
Subject(s) - macrocytosis , medicine , sunitinib , sorafenib , renal cell carcinoma , gastroenterology , oncology , discontinuation , anemia , hepatocellular carcinoma
Abstract Increases in the mean corpuscular volume ( MCV ) have been observed in patients with metastatic renal cell carcinoma ( mRCC ) on tyrosine kinase inhibitor ( TKI ) treatment; however, its association with progression‐free‐survival ( PFS ) is unknown. We aimed to characterize TKI ‐associated macrocytosis in mRCC and its relationship with PFS. Retrospective review of data on macrocytosis and thyroid dysfunction on mRCC patients treated with sunitinib and/or sorafenib. These results are evaluated in the context of our previous report on the association of hypothyroidism in this setting. We assessed PFS as clinically defined by the treating physician. Seventy‐four patients, 29 of whom received both drugs, were included. A treatment period was defined as time from initiation to discontinuation of either sunitinib or sorafenib; 103 treatment periods [sorafenib (47), sunitinib (56)] were analyzed. Macrocytosis was found in 55 and 8% of sunitinib‐ and sorafenib‐treated patients, respectively, P < 0.001. The median time to developing macrocytosis was 3 months (m, range 1–7). Median PFS in sunitinib‐treated patients was 11 m (95% CI : 6–19). Median PFS was higher among those with macrocytosis compared to normocytosis (21 m [95% CI : 11–25] vs. 4 m [95% CI : 3–8] P = 0.0001). Macrocytosis and hypothyroidism were two significant predictors of PFS . The greatest difference in PFS among all patients was observed in patients with both macrocytosis and hypothyroidism (25 m), compared to the normocytic and euthyroid patients (5 m) ( P < 0.0001). Sunitinib‐related macrocytosis was associated with prolonged PFS , and concurrent development of hypothyroidism and macrocytosis further prolonged PFS . Increased MCV may have a role as a predictive biomarker for sunitinib. Prospective studies accounting for other known prognostic factors are needed to confirm this finding.